Elucidata Briefing Note
Axendia was briefed by Abhishek Jha, Co-Founder and CEO at Elucidata. The company was founded a decade ago out of Jha’s experience as a computational biologist at MIT and the University of Chicago and shaped further by his time at a biotech start-up that has since brought four first-in-class drugs through to FDA approval. Elucidata was founded on the premise that the tools and services that R&D scientists need to make sense of complex, multimodal data did not exist. The company operates out of offices in the US, India, and Japan and has worked with 90 R&D organizations – from early stage biotechs to Top 20 pharma.
The Problem: A Heterogeneous, Fragmented Data Landscape
The challenge that Elucidata is addressing is one that Axendia has observed across many conversations in this space. The life sciences R&D data environment is deeply heterogeneous, and connecting data across systems, sources, and teams has remained incredibly difficult. “I see this problem remaining unsolved for the foreseeable future,” stated Jha, “but that’s also what gets us excited.”
“Our goal,” Jha continues, “is not to propose a replacement for these technology stacks. It is to make them work better – and more specifically, to make the technology work for a very specific scientific purpose. Most of the time, there are very solid elements to their existing ecosystems, so we actively discourage customers from switching altogether. If you put good plumbing around those elements, it can be very effective.”
A Four-Layer Framework That is Use-Case First
Elucidata approaches the enterprise R&D data problem using a four-layer framework:
Importantly, Elucidata begins with the use case. “This was a hard-won lesson for us,” states Jha. “We’d initially thought we could bring data from all different sources, harmonize it, and make it useful for all use cases across all stakeholders. We just weren’t able to meet the quality standards we’d promised our customers. Quality is a function of the use case, not a function of the data source.” Jha characterizes this pivot as starting out a mile wide and an inch deep and shifting to much greater depth – “an inch wide and a mile deep.”
The implications for AI readiness are significant. Jha was candid that plugging a curated knowledge graph into a frontier large language model (LLM) and expecting high quality results did not yield what they’d expected. The company has instead invested deeply in what it calls intent parsing – the ability to accurately interpret a scientist’s query, turn it into a structured plan, and return a result that is both accurate and explainable. “Getting a response is easy enough,” Jha said. “Getting a good quality response is very hard.”
Data-Centric AI: A Different Thesis for Life Sciences
Jha presented his argument for why traditional AI is not well-suited to life sciences. He refers to the “out-of-distribution problem” – the core assumption of supervised learning, that the data seen in deployment will resemble training data, is systematically violated in scientific contexts. Jha gives the example of clinical trials where there are thousands of patients, a relatively small number when you think of training data. When an outlier is identified – a patient who does not respond to the treatment in the same way – our instinct is to label that datapoint as noise. What we’re typically ignoring, Jha states, is that such a response might represent the next billion-dollar program.
“We have consistently shown that a dollar or an hour spent on getting the data cleaned up and integrated with different types of data improves the performance of the AI model,” Jha said. “The colloquial way to describe it is that it’s good at pattern matching. What if you have an observation that does not match a pattern? Do you give up? This is an opportunity to provide more clarity using these tools. There is a lot of value to be derived.”
Outcome-Focused: Services-First, by Design
Perhaps the most distinctive aspect of Elucidata is its deliberate positioning as a managed services company rather than as a SaaS vendor. Jha was unequivocal on this point: “I want to be very explicit. We are a fully managed services company. We are not a SaaS company. I’m okay with that label.”
His reasoning is rooted in where customers are looking for the most value – in the last mile of configuration that turns a data framework into something that answers a specific scientific question. “I have to prioritize one stakeholder, and that’s my market. They see value in that last mile of configuration. The rest of the complexity – how to serve and how to deliver – that’s on me.”
This is not, Jha acknowledged, where the company started. It reflects a conviction built through experience – and through the discipline of asking, consistently, what customers care about rather than what the company has built. “That’s a hard one for scientists and engineers like me,” he said, “because we get excited about things we build. But it requires discipline to talk about what my customers care about, what do they want.”
This point of view explains why our discussion did not revolve around a singular product. Elucidata’s platform, Polly, is the technology layer through which the four-layer framework (data, evidence, mechanistic analysis, and consumption) are delivered. Not every customer needs all elements, and each customer comes to the table with their legacy ecosystem, so Elucidata does not push Polly as the solution. The team’s aim is to engage around the different elements most relevant for a specific use case. “I would rather lead less with what we do and more with what our customers care about,” Jha said. “That’s the shift we want to make. The metric that demonstrates we are doing the right thing is the 40 programs that we have helped progress to IND and beyond. These are the outcomes that matter.”
In Brief
As Axendia’s own primary research has found, data quality and readiness remain among the top concerns life sciences organizations have about AI adoption. Elucidata’s focus on exactly that problem – building high-quality, use-case-specific data products at scale, with the expert services to match – addresses a real and persistent gap.
We will continue to provide updates on Elucidata as they become available.
Related Content:
- Navigating AI’s Peril and Promise: The Executive Perspective
- 2026 Life Sciences Radar: How to Turn Disruption into Competitive Advantage
- Accelerating the Trajectory of Digital Sustainability in the Lab
Stay Connected with Axendia!
Stay at the forefront of innovation and technology in life sciences, healthcare, and space-enabled research by connecting with Axendia.
- Follow us on LinkedIn: Join our professional network and stay updated on the latest insights, trends, and case studies. Connect with Axendia on LinkedIn
- Subscribe to Our Updates: Get exclusive insights and thought leadership articles delivered straight to your inbox. Sign up for our newsletter
- Share Your Thoughts: We’d love to hear from you! Contact us to discuss your ideas, challenges, or opportunities. Email Axendia
Let’s drive innovation together!
Ready to unlock new opportunities and drive success? Schedule an Analyst Inquiry
The opinions and analysis expressed in this post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this post is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This post is not intended to endorse any company or product and should not be attributed as such.